ES2192420T3 - Utilizacion de una composicion farmaceutica que comprende un agente anticanceroso y al menos un peptido. - Google Patents

Utilizacion de una composicion farmaceutica que comprende un agente anticanceroso y al menos un peptido.

Info

Publication number
ES2192420T3
ES2192420T3 ES99972932T ES99972932T ES2192420T3 ES 2192420 T3 ES2192420 T3 ES 2192420T3 ES 99972932 T ES99972932 T ES 99972932T ES 99972932 T ES99972932 T ES 99972932T ES 2192420 T3 ES2192420 T3 ES 2192420T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
peptide
agent
target agent
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99972932T
Other languages
English (en)
Inventor
Jamal Temsamani
Michel Kaczorek
De Verdiere Annik Colin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synt EM SA
Original Assignee
Synt EM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt EM SA filed Critical Synt EM SA
Application granted granted Critical
Publication of ES2192420T3 publication Critical patent/ES2192420T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Utilización de una composición farmacéutica que comprende un agente anticanceroso y al menos un péptido. La presente invención concierne a la utilización de péptidos para la vectorización de agentes anticancerosos para aplicaciones en el tratamiento y/o la prevención del cáncer, más concretamente en el campo de la quimio-resistencia.
ES99972932T 1998-11-30 1999-11-26 Utilizacion de una composicion farmaceutica que comprende un agente anticanceroso y al menos un peptido. Expired - Lifetime ES2192420T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9815073A FR2786398B1 (fr) 1998-11-30 1998-11-30 Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide

Publications (1)

Publication Number Publication Date
ES2192420T3 true ES2192420T3 (es) 2003-10-01

Family

ID=9533369

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99972932T Expired - Lifetime ES2192420T3 (es) 1998-11-30 1999-11-26 Utilizacion de una composicion farmaceutica que comprende un agente anticanceroso y al menos un peptido.

Country Status (13)

Country Link
US (1) US7527792B1 (es)
EP (1) EP1135169B1 (es)
JP (1) JP2002538080A (es)
AT (1) ATE232398T1 (es)
AU (1) AU769766B2 (es)
CA (1) CA2352134A1 (es)
DE (1) DE69905392T2 (es)
DK (1) DK1135169T3 (es)
ES (1) ES2192420T3 (es)
FR (1) FR2786398B1 (es)
IL (2) IL143012A0 (es)
PT (1) PT1135169E (es)
WO (1) WO2000032237A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
FR2821272B1 (fr) * 2001-02-23 2004-12-17 Synt Em Composes constitues d'une molecule analgesique liee a un vecteur capable de vectoriser ladite molecule a travers la barriere hematoencephalique et compositions pharmaceutiques les contenant
FR2830016B1 (fr) * 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau
AU2002340561B2 (en) * 2001-10-16 2007-11-15 Synt:Em S.A. Use of peptide vectors to improve the immune response to antigens
FR2840810B1 (fr) * 2002-06-18 2005-02-11 Synt Em Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
US11564991B2 (en) 2014-11-12 2023-01-31 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability
US10322189B2 (en) 2014-11-12 2019-06-18 University Of Mississippi Medical Center Kidney-targeted drug delivery systems
KR102015524B1 (ko) 2016-12-26 2019-08-29 인터올리고 주식회사 압타머-약물 콘쥬게이트 및 그 용도
US11248038B2 (en) 2019-03-29 2022-02-15 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
WO1998046250A1 (en) * 1997-04-14 1998-10-22 The Regents Of The University Of California Peptide antiestrogen compositions and methods for treating breast cancer
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
FR2830016B1 (fr) 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau

Also Published As

Publication number Publication date
EP1135169A1 (fr) 2001-09-26
AU769766B2 (en) 2004-02-05
US7527792B1 (en) 2009-05-05
DE69905392T2 (de) 2003-10-09
IL143012A0 (en) 2002-04-21
PT1135169E (pt) 2003-06-30
FR2786398A1 (fr) 2000-06-02
FR2786398B1 (fr) 2002-12-27
WO2000032237A1 (fr) 2000-06-08
DE69905392D1 (de) 2003-03-20
AU1391100A (en) 2000-06-19
JP2002538080A (ja) 2002-11-12
IL143012A (en) 2007-05-15
EP1135169B1 (fr) 2003-02-12
DK1135169T3 (da) 2003-06-10
CA2352134A1 (fr) 2000-06-08
ATE232398T1 (de) 2003-02-15

Similar Documents

Publication Publication Date Title
BR9911724A (pt) Ciclosporina que tem um perfil de atividade melhorado
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
SV2002000343A (es) Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
ES2137372T3 (es) Solucion antifungica para las uñas.
ES2192420T3 (es) Utilizacion de una composicion farmaceutica que comprende un agente anticanceroso y al menos un peptido.
PT1077680E (pt) Metodo de fabrico de uma forma de dosagem de agente activo com bandas de libertacao prolongada
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
NO975858D0 (no) Anvendelse av et ekstrakt av Cimicifuga racemosa
WO2003053180A3 (de) Wirkstoffhaltige unterwäsche
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
HK1028876A1 (en) Pharmacuetical compositions comprising an aldose reductase inhibitor and an ace inhibitor
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
DE69917796D1 (de) Decursin-enthaltende pharmazeutische zusammensetzungen
DE60122973D1 (de) Mittel, insbesondere für Kosmetika, enthaltend DHEA und/oder Vorstufe oder Derivate davon, und mindestens eine Verbindung, die die Glykosaminoglykane-Synthese erhöht
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
IT1274655B (it) Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
ES2150929T3 (es) Procedimiento para la obtencion de 3,7-dialquilxantinas a partir de 3-alquilxantinas.
PA8454301A1 (es) Composiciones solubilizadas de sertralina
ES2190201T3 (es) Medicamento para la profilaxis y/o el tratamiento del carcinoma de mama que contiene un inhibidor esteroideo de la aromatasa.
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.